Table 1.
Demographic and clinical characteristics and biomarkers in 96 HTx patients subdivided according to occurrence or absence of cardiovascular events.
| Variables | All | No events | Events | No events versus events |
|---|---|---|---|---|
| N = 96 | n = 75 | n = 21 | P | |
| Recipient age at HTx (years) | 47 ± 16 | 49 ± 15 | 44 ± 16 | 0.19 |
| Donor age (years) | 40 ± 15 | 39 ± 13 | 42 ± 15 | 0.4 |
| Total ischemic time (min) | 183 ± 54 | 186 ± 52 | 168 ± 61 | 0.1 |
| Score rejection (%) | 12 ± 14 | 13 ± 17 | 12 ± 13 | 0.9 |
| Cytomegalovirus infection (%) | 35 (35%) | 29 (39%) | 6 (30%) | 0.6 |
| Plasma creatinine, umol/L | 125 ± 106 | 104 ± 44 | 159 ± 120 | 0.002 |
| Cardiovascular risk factors | ||||
| Pre-HTx hyperlipemia (%) | 28 (29%) | 18 (26%) | 10 (55%) | 0.02 |
| Post-HTx hypertension (%) | 53 (55%) | 39 (55%) | 14 (78%) | 0.7 |
| Post-HTx diabetes (%) | 27 (28%) | 22 (31%) | 6 (33%) | 0.1 |
| CAV | 51 (53%) | 30 (40%) | 21 (100%) | |
| Hs-cTnT (ng/L) | 25 ± 27 | 20 ± 18 | 56 ± 45 | 0.04 |
| sAXL (ng/L) | 72 ± 35 | 26 ± 26 | 98 ± 51 | 0.01 |
HTx: heart transplantation; CAV: cardiac allograft vasculopathy; hs-cTnT: cardiac troponin T measured with methods of high sensitivity; sAXL: soluble form of the AXL receptor.